WEATHER ALERT
Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop
Read full article: Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock dropEli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations.
Weight loss, diabetes drugs propel Eli Lilly to largely better-than-expected forecast for 2024
Read full article: Weight loss, diabetes drugs propel Eli Lilly to largely better-than-expected forecast for 2024Eli Lilly rode soaring demand for diabetes and weight-loss treatments to a better-than-expected finish in 2023, and the drugmaker expects momentum to carry into the new year.
Supply problems and insurance issues make popular weight-loss drugs hard to get
Read full article: Supply problems and insurance issues make popular weight-loss drugs hard to getSupply problems and insurance complications have made it difficult for many patients to start and stay on new prescription medications used to treat obesity.
Soaring sales of diabetes drug Mounjaro, widely used for weight loss, sends Eli Lilly to new heights
Read full article: Soaring sales of diabetes drug Mounjaro, widely used for weight loss, sends Eli Lilly to new heightsEli Lilly’s diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected.